Enteral immunomodulating nutrition modifies the gastrointestinal microbiota as well as improves the intestinal barrier integrity in patients with gastric and colorectal cancer in the perioperative period. As a consequence, it contributes to the reduction of the incidence of postoperative complications and diarrhea, which is a side effect of anti-cancer treatment often used preoperatively in this group of cancers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
80
Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.
The impact of immunonutrition on gut microbiota in gastric and colorectal cancer patients.
The composition of gut microbiota (bacteria and fungi) will be assessed from stools. The amounts of bacteria/fungi will be presented using bioinformatics tools and there is no precisely described units (only the total number).
Time frame: at baseline and after 7 and 10 days
The impact of immunonutrition on intestinal permeability in gastric and colorectal cancer patients.
The ratio lactulose/mannitol will be described to assess intestinal permeability. There is no units. Only ratio of two numbers.
Time frame: at baseline and after 7 and 10 days
The impact of immunonutrition on intestines in gastric and colorectal cancer patients.
The calprotecin will be assessed. The unit is μg/g.
Time frame: at baseline and after 7 and 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.